{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig67orvbtlm6qq7tgfz553gvn4riz2uomecqn4mz6uajxltfpcbvy",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mh727m2ot5q2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibmgt76hgixp7iq2le65iejjc5o6s5yv2akkkp2lbn5zgkc4nycdu"
    },
    "mimeType": "image/jpeg",
    "size": 72729
  },
  "path": "/2026/03/16/structure-therapeutics-obesity-pill-aleniglipron-weight-loss/?utm_campaign=rss",
  "publishedAt": "2026-03-16T11:57:11.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "drug development",
    "Obesity",
    "STAT+"
  ],
  "textContent": "An experimental obesity pill from Structure Therapeutics helped patients lose significant weight in a mid-stage trial, with a Phase 3 study in the works.",
  "title": "STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill",
  "updatedAt": "2026-03-16T15:35:43.000Z"
}